Archie Tse

4.4k total citations · 1 hit paper
59 papers, 3.3k citations indexed

About

Archie Tse is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Archie Tse has authored 59 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 22 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Archie Tse's work include Cancer therapeutics and mechanisms (13 papers), Cancer-related Molecular Pathways (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Archie Tse is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Cancer-related Molecular Pathways (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Archie Tse collaborates with scholars based in United States, United Kingdom and China. Archie Tse's co-authors include Gary K. Schwartz, Richard D. Carvajal, David P. Kelsen, Manish A. Shah, Nancy E. Kemeny, Jinru Shia, David S. Klimstra, Leonard B. Saltz, Deborah Schrag and Audrey Hamilton and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Archie Tse

57 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 848 citations Jinru Shia, Nancy E. Kemeny et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Archie Tse United States	23	2.0k	1.4k	947	419	349	59	3.3k
Xiuning Le United States	32	1.8k 0.9×	1.3k 0.9×	2.0k 2.1×	301 0.7×	217 0.6×	168	3.5k
Masao Kameyama Japan	31	1.3k 0.7×	1.3k 0.9×	1.1k 1.1×	225 0.5×	930 2.7×	158	3.4k
Armand de Gramont France	28	1.8k 0.9×	1.3k 0.9×	708 0.7×	180 0.4×	590 1.7×	110	3.2k
Richard Sesboüé France	27	1.2k 0.6×	1.0k 0.7×	806 0.9×	275 0.7×	234 0.7×	91	2.7k
Wing‐Kai Chan Taiwan	22	1.4k 0.7×	1.4k 1.0×	1.2k 1.3×	143 0.3×	307 0.9×	57	3.2k
Susana Roselló Spain	31	2.3k 1.2×	885 0.6×	1.0k 1.1×	226 0.5×	686 2.0×	89	3.6k
Henning Reis Germany	33	891 0.5×	1.1k 0.7×	825 0.9×	233 0.6×	972 2.8×	182	3.1k
Silvia Benvenuti Italy	20	1.6k 0.8×	969 0.7×	923 1.0×	111 0.3×	223 0.6×	40	2.6k
Tina Cascone United States	30	1.8k 0.9×	1.4k 0.9×	1.6k 1.7×	97 0.2×	249 0.7×	104	3.4k
Scott A. Boerner United States	23	852 0.4×	1.2k 0.8×	337 0.4×	275 0.7×	153 0.4×	40	2.2k

Countries citing papers authored by Archie Tse

Since Specialization

Citations

This map shows the geographic impact of Archie Tse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Archie Tse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Archie Tse more than expected).

Fields of papers citing papers by Archie Tse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Archie Tse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Archie Tse. The network helps show where Archie Tse may publish in the future.

Co-authorship network of co-authors of Archie Tse

This figure shows the co-authorship network connecting the top 25 collaborators of Archie Tse. A scholar is included among the top collaborators of Archie Tse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Archie Tse. Archie Tse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soulières, Denis, Yi‐Chun Liu, Kedar Kirtane, et al.. (2025). LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 36. S1592–S1592.

Kotasek, Dusan, Morteza Aghmesheh, Thomas Yau, et al.. (2024). Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study. Cancer. 130(11). 1991–2002. 1 indexed citations

Sheng, Yucheng, Shu‐Wen Teng, Jingru Wang, Hao Wang, & Archie Tse. (2023). Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302. CPT Pharmacometrics & Systems Pharmacology. 13(3). 437–448. 9 indexed citations

Wang, Siyuan, et al.. (2023). Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia. European Journal of Clinical Pharmacology. 80(1). 105–113. 1 indexed citations

Day, Daphne, John Park, Jermaine Coward, et al.. (2023). A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer. British Journal of Cancer. 129(10). 1608–1618. 4 indexed citations

Yau, Thomas, Rasha Cosman, Miranda A. Moore, et al.. (2021). 138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors. Annals of Oncology. 32. S1437–S1438. 2 indexed citations

Shen, Lin, Ye Guo, W. Li, et al.. (2020). 987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 31. S690–S691. 9 indexed citations

Ishizawa, Jo, Kenji Nakamaru, Takahiko Seki, et al.. (2018). Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Research. 78(10). 2721–2731. 44 indexed citations

Harrington, Kevin J., Joshua Brody, James Strauss, et al.. (2018). Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Annals of Oncology. 29. viii712–viii712. 201 indexed citations

10.

Chen, Cong, Keaven M. Anderson, Devan V. Mehrotra, Eric H. Rubin, & Archie Tse. (2017). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. Contemporary Clinical Trials. 64. 238–242. 41 indexed citations

11.

McNeely, Samuel, Chiara Conti, Tahir Sheikh, et al.. (2010). Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle. 9(5). 995–1004. 68 indexed citations

12.

Jarnagin, William R., Lawrence H. Schwartz, David H. Gültekin, et al.. (2009). Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Annals of Oncology. 20(9). 1589–1595. 138 indexed citations

13.

Tse, Archie, Nian Wu, Dina Patel, Dana Haviland, & Nancy E. Kemeny. (2009). A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemotherapy and Pharmacology. 64(5). 935–944. 10 indexed citations

14.

Tse, Archie, David S. Klimstra, Mithat Gönen, et al.. (2008). A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. Clinical Cancer Research. 14(20). 6704–6711. 49 indexed citations

15.

Zabludoff, Sonya, Chun Deng, Michael Grondine, et al.. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular Cancer Therapeutics. 7(9). 2955–2966. 333 indexed citations

16.

Tse, Archie, Katherine G. Rendahl, Tahir Sheikh, et al.. (2007). CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo. Clinical Cancer Research. 13(2). 591–602. 117 indexed citations

17.

Tse, Archie, Greer A. Raggio, M. Morse, & Nancy E. Kemeny. (2006). A phase I clinical and pharmacokinetic study of escalating doses of fixed rate and escalating infusion duration of gemcitabine given via an intrahepatic pump for patients with hepatic metastases. Journal of Clinical Oncology. 24(18_suppl). 14035–14035. 1 indexed citations

18.

Tse, Archie & Gary K. Schwartz. (2004). Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe. Cancer Research. 64(18). 6635–6644. 76 indexed citations

19.

Tse, Archie, Kevin E. Brigle, Shirley M. Taylor, & Richard G. Moran. (1998). Mutations in the Reduced Folate Carrier Gene Which Confer Dominant Resistance to 5,10-Dideazatetrahydrofolate. Journal of Biological Chemistry. 273(40). 25953–25960. 52 indexed citations

20.

Tse, Archie & Richard G. Moran. (1998). Cellular Folates Prevent Polyglutamation of 5,10-Dideazatetrahydrofolate. Journal of Biological Chemistry. 273(40). 25944–25952. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact